BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2480187)

  • 1. Cellular metabolism of 1-beta-D-arabinofuranosyl-5-azacytosine and incorporation into DNA and RNA of human lymphoid CEM/0 and CEM/dCk(-) cells.
    Avramis VI; Powell WC; Mecum RA
    Cancer Chemother Pharmacol; 1989; 25(1):19-24. PubMed ID: 2480187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular metabolism of 5,6-dihydro-5-azacytidine and its incorporation into DNA and RNA of human lymphoid cells CEM/O and CEM/dCk(-).
    Avramis VI; Powell WC; Mecum RA
    Cancer Chemother Pharmacol; 1989; 24(3):155-60. PubMed ID: 2472227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical pharmacology and DNA methylation studies of arabinosyl 5-azacytidine and 5,6-dihydro-5-azacytidine in two human leukemia cell lines PER-145 and PER-163.
    Kees UR; Avramis VI
    Anticancer Drugs; 1995 Apr; 6(2):303-10. PubMed ID: 7540895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
    Avramis VI; Mecum RA; Nyce J; Steele DA; Holcenberg JS
    Cancer Chemother Pharmacol; 1989; 24(4):203-10. PubMed ID: 2473850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 5-azacytidine and congeners on DNA methylation and expression of deoxycytidine kinase in the human lymphoid cell lines CCRF/CEM/0 and CCRF/CEM/dCk-1.
    Antonsson BE; Avramis VI; Nyce J; Holcenberg JS
    Cancer Res; 1987 Jul; 47(14):3672-8. PubMed ID: 2439195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.
    Kong XB; Tong WP; Chou TC
    Mol Pharmacol; 1991 Feb; 39(2):250-7. PubMed ID: 1705001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
    Ramilo-Torno LV; Avramis VI
    Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and 1-beta-D-arabinofuranosylcytosine by cyclopentenyl cytosine.
    Grem JL; Allegra CJ
    Cancer Res; 1990 Nov; 50(22):7279-84. PubMed ID: 1699659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism of 1-beta-D-arabinofuranosyl-5-azacytosine and incorporation into DNA of human T-lymphoblastic cells (Molt-4).
    Townsend A; Leclerc JM; Dutschman G; Cooney D; Cheng YC
    Cancer Res; 1985 Aug; 45(8):3522-8. PubMed ID: 2410096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arabinosyl-5-azacytosine: mechanisms of native and acquired resistance.
    Ahluwalia GS; Cohen MB; Kang GJ; Arnold ST; McMahon JB; Dalal M; Wilson YA; Cooney DA; Balzarini J; Johns DG
    Cancer Res; 1986 Sep; 46(9):4479-85. PubMed ID: 2425954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence-dependent interaction of 5-fluorouracil and arabinosyl-5-azacytosine or 1-beta-D-arabinofuranosylcytosine.
    Grem JL; Allegra CJ
    Biochem Pharmacol; 1991 Jul; 42(2):409-18. PubMed ID: 1713459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
    Nandy P; Lien EJ; Avramis VI
    Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line.
    Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
    BMC Cancer; 2014 Jul; 14():547. PubMed ID: 25070259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
    Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH
    Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
    Grant S; Bhalla K; McCrady C
    Leuk Res; 1991; 15(4):205-13. PubMed ID: 2030601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells.
    Gandhi V; Mineishi S; Huang P; Yang Y; Chubb S; Chapman AJ; Nowak BJ; Hertel LW; Plunkett W
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):61-7. PubMed ID: 7481847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate.
    Catapano CV; Chandler KB; Fernandes DJ
    Cancer Res; 1991 Apr; 51(7):1829-35. PubMed ID: 1706219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology.
    Wang LM; White JC; Capizzi RL
    Cancer Chemother Pharmacol; 1990; 25(6):418-24. PubMed ID: 2311169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of action of 5-AZA-dC: induced DNA hypomethylation does not lead to aberrant gene expression in human leukemic CEM cells.
    Bouchard J
    Leuk Res; 1989; 13(8):715-22. PubMed ID: 2477646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.
    Grant S; Turner A; Nelms P; Yanovich S
    Leukemia; 1995 May; 9(5):808-14. PubMed ID: 7769843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.